Summary
27.70 0.26(0.95%)10/04/2024
Atricure Inc (ATRC)
Atricure Inc (ATRC)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.91 | -1.72 | 5.52 | 17.12 | 5.93 | -32.52 | 10.10 | 96.73 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 27.70 | |
| Open | 27.73 | |
| High | 28.22 | |
| Low | 27.51 | |
| Volume | 333,719 | |
| Change | 0.25 | |
| Change % | 0.91 | |
| Avg Volume (20 Days) | 400,237 | |
| Volume/Avg Volume (20 Days) Ratio | 0.83 | |
| 52 Week Range | 18.94 - 43.00 | |
| Price vs 52 Week High | -35.58% | |
| Price vs 52 Week Low | 46.25% | |
| Range | -0.11 | |
| Gap Up/Down | -0.12 | |
Fundamentals | ||
| Market Capitalization (Mln) | 1,384 | |
| EBIDTA | -19,908,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | -1.1800 | |
| WallStreet Target Price | 49.00 | |
| Book Value | 9.4320 | |
| Earnings Per Share | -0.8000 | |
| EPS Estimate Current Quarter | -0.2300 | |
| EPS Estimate Next Quarter | -0.1600 | |
| EPS Estimate Current Year | -0.7800 | |
| EPS Estimate Next Year | -0.6300 | |
| Diluted EPS (TTM) | -0.8000 | |
| Revenues | ||
| Profit Marging | -0.0898 | |
| Operating Marging (TTM) | -0.1003 | |
| Return on asset (TTM) | -0.0386 | |
| Return on equity (TTM) | -0.0817 | |
| Revenue TTM | 414,601,984 | |
| Revenue per share TTM | 8.9230 | |
| Quarterly Revenue Growth (YOY) | 0.1640 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 245,940,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 2.4998 | |
| Revenue Enterprise Value | 2.7616 | |
| EBITDA Enterprise Value | -135.9667 | |
| Shares | ||
| Shares Outstanding | 48,382,300 | |
| Shares Float | 46,777,967 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.06 | |
| Insider (%) | 3.07 | |
| Institutions (%) | 101.14 | |
09/05 07:23 EST - time.com
Faisal Al Bannai
In 2023, the Advanced Technology Research Council (ATRC), an arm of the Abu Dhabi government, spent millions of dollars building a series of large language models. ATRC secretary general Faisal Al Bannai then decided to release them online for free, reasoning that if they were as good as the team’s internal testing showed, it would…
Faisal Al Bannai
In 2023, the Advanced Technology Research Council (ATRC), an arm of the Abu Dhabi government, spent millions of dollars building a series of large language models. ATRC secretary general Faisal Al Bannai then decided to release them online for free, reasoning that if they were as good as the team’s internal testing showed, it would…
08/28 13:15 EST - zacks.com
AtriCure's Shares Likely to Benefit From New AtriClip Device Sales
ATRC announces the treatment of the first patient using the AtriClip FLEX-Mini device.
AtriCure's Shares Likely to Benefit From New AtriClip Device Sales
ATRC announces the treatment of the first patient using the AtriClip FLEX-Mini device.
08/27 08:00 EST - businesswire.com
AtriCure Announces that the First Patient has been Treated with the Revolutionary AtriClip® FLEX-Mini™ Device
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the first patient was treated with the AtriClip® FLEX-Mini™ device, which recently received 510(k) clearance. The AtriClip FLEX-Mini sets a new standard as the smallest profile surgical LAA device on the market and builds upon the proven technology of.
AtriCure Announces that the First Patient has been Treated with the Revolutionary AtriClip® FLEX-Mini™ Device
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the first patient was treated with the AtriClip® FLEX-Mini™ device, which recently received 510(k) clearance. The AtriClip FLEX-Mini sets a new standard as the smallest profile surgical LAA device on the market and builds upon the proven technology of.
08/23 13:10 EST - zacks.com
AtriCure's (ATRC) AtriClip Receives Expanded CE-Mark Indication
AtriCure (ATRC) announces the receipt of an expanded CE-Mark indication for its AtriClip devices for reducing strokes in patients with Afib.
AtriCure's (ATRC) AtriClip Receives Expanded CE-Mark Indication
AtriCure (ATRC) announces the receipt of an expanded CE-Mark indication for its AtriClip devices for reducing strokes in patients with Afib.
07/31 00:01 EST - seekingalpha.com
AtriCure, Inc. (ATRC) Q2 2024 Earnings Call Transcript
AtriCure, Inc. (NASDAQ:ATRC ) Q2 2024 Earnings Conference Call July 30, 2024 4:30 PM ET Company Participants Marissa Bych - Investor Relations Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants Lilia Lozada - JPMorgan John Newman - Canaccord Genuity John McAulay - Stifel Financial Corp. Sam Eiber - BTIG Danielle Antalffy - UBS Daniel Stauder - Citizens JMP Suraj Kalia - Oppenheimer & Co. Joseph Conway - Needham & Company Operator Good afternoon, And welcome to AtriCure's Second Quarter 2024 Earnings Conference Call. This call is being recorded for replay purposes.
AtriCure, Inc. (ATRC) Q2 2024 Earnings Call Transcript
AtriCure, Inc. (NASDAQ:ATRC ) Q2 2024 Earnings Conference Call July 30, 2024 4:30 PM ET Company Participants Marissa Bych - Investor Relations Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants Lilia Lozada - JPMorgan John Newman - Canaccord Genuity John McAulay - Stifel Financial Corp. Sam Eiber - BTIG Danielle Antalffy - UBS Daniel Stauder - Citizens JMP Suraj Kalia - Oppenheimer & Co. Joseph Conway - Needham & Company Operator Good afternoon, And welcome to AtriCure's Second Quarter 2024 Earnings Conference Call. This call is being recorded for replay purposes.
07/30 18:31 EST - zacks.com
AtriCure (ATRC) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
AtriCure (ATRC) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
07/30 18:11 EST - zacks.com
AtriCure (ATRC) Reports Q2 Loss, Lags Revenue Estimates
AtriCure (ATRC) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.12 per share a year ago.
AtriCure (ATRC) Reports Q2 Loss, Lags Revenue Estimates
AtriCure (ATRC) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.12 per share a year ago.
07/29 08:00 EST - businesswire.com
AtriCure to Participate in the Canaccord Genuity 44th Annual Global Growth Conference
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Canaccord Genuity 44th Annual Global Growth Conference. AtriCure's management is scheduled to present on Tuesday, August 13, 2024, at 10:30 am EST. Interested parties may access a live audio webcast of.
AtriCure to Participate in the Canaccord Genuity 44th Annual Global Growth Conference
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Canaccord Genuity 44th Annual Global Growth Conference. AtriCure's management is scheduled to present on Tuesday, August 13, 2024, at 10:30 am EST. Interested parties may access a live audio webcast of.
07/24 11:15 EST - zacks.com
AtriCure (ATRC) Gains China Approval for AtriClip LAA System
AtriCure (ATRC) receives NMPA approval to market AtriClip Left Atrial Appendage Exclusion System in China, marking a significant step in global expansion.
AtriCure (ATRC) Gains China Approval for AtriClip LAA System
AtriCure (ATRC) receives NMPA approval to market AtriClip Left Atrial Appendage Exclusion System in China, marking a significant step in global expansion.
06/28 06:50 EST - investorplace.com
Have 20 Bucks? 7 Low-Priced Stocks That Could Double by 2025
Low-priced stocks to buy with the potential to double within the next year or so have inherent appeal for investors. Individual shares are affordable making it relatively easy to establish a stake.
Have 20 Bucks? 7 Low-Priced Stocks That Could Double by 2025
Low-priced stocks to buy with the potential to double within the next year or so have inherent appeal for investors. Individual shares are affordable making it relatively easy to establish a stake.
05/15 08:00 EST - businesswire.com
AtriCure to Participate in the 2024 Leerink Partners Healthcare Crossroads Conference
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Leerink Partners Healthcare Crossroads Conference. AtriCure's management is scheduled to participate in a fireside chat on Wednesday, May 29, 2024, at 10:40 a.m. Central Time. Interested parties may acc.
AtriCure to Participate in the 2024 Leerink Partners Healthcare Crossroads Conference
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Leerink Partners Healthcare Crossroads Conference. AtriCure's management is scheduled to participate in a fireside chat on Wednesday, May 29, 2024, at 10:40 a.m. Central Time. Interested parties may acc.
05/02 01:48 EST - seekingalpha.com
AtriCure, Inc. (ATRC) Q1 2024 Earnings Call Transcript
AtriCure, Inc. (NASDAQ:ATRC ) Q1 2024 Earnings Conference Call May 1, 2024 4:30 PM ET Company Participants Marissa Bych - Investor Relations Mike Carrel - President and Chief Executive Officer Angie Wirick - Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan William Plovanic - Canaccord Genuity Marie Thibault - BTIG Danielle Antalffy - UBS Daniel Stauder - Citizens JMP Mike Matson - Needham & Company Suraj Kalia - Oppenheimer Operator Good afternoon and welcome to AtriCure's First Quarter 2024 Earnings Conference Call. This call is being recorded for replay purposes.
AtriCure, Inc. (ATRC) Q1 2024 Earnings Call Transcript
AtriCure, Inc. (NASDAQ:ATRC ) Q1 2024 Earnings Conference Call May 1, 2024 4:30 PM ET Company Participants Marissa Bych - Investor Relations Mike Carrel - President and Chief Executive Officer Angie Wirick - Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan William Plovanic - Canaccord Genuity Marie Thibault - BTIG Danielle Antalffy - UBS Daniel Stauder - Citizens JMP Mike Matson - Needham & Company Suraj Kalia - Oppenheimer Operator Good afternoon and welcome to AtriCure's First Quarter 2024 Earnings Conference Call. This call is being recorded for replay purposes.
05/01 21:00 EST - zacks.com
Compared to Estimates, AtriCure (ATRC) Q1 Earnings: A Look at Key Metrics
The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Compared to Estimates, AtriCure (ATRC) Q1 Earnings: A Look at Key Metrics
The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
05/01 18:31 EST - zacks.com
AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates
AtriCure (ATRC) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.23 per share a year ago.
AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates
AtriCure (ATRC) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.23 per share a year ago.
05/01 16:01 EST - businesswire.com
AtriCure Reports First Quarter 2024 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2024 financial results. “We are proud to announce a strong start to 2024, marked by growth across each of our franchises worldwide,” said Michael Carrel, President and Chief Executive Officer at AtriCure. “We remain diligently focused on expand.
AtriCure Reports First Quarter 2024 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2024 financial results. “We are proud to announce a strong start to 2024, marked by growth across each of our franchises worldwide,” said Michael Carrel, President and Chief Executive Officer at AtriCure. “We remain diligently focused on expand.
04/19 10:46 EST - zacks.com
AtriCure's (ATRC) cryoSPHERE+ Probe to Aid in Pain Management
AtriCure (ATRC) unveils its cryoSPHERE+ cryoablation probe, which is intended to reduce freeze times and aid in postoperative pain management.
AtriCure's (ATRC) cryoSPHERE+ Probe to Aid in Pain Management
AtriCure (ATRC) unveils its cryoSPHERE+ cryoablation probe, which is intended to reduce freeze times and aid in postoperative pain management.
04/18 08:00 EST - businesswire.com
AtriCure Announces Launch of the cryoSPHERE®+ Probe for Post-Operative Pain Management
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has launched the cryoSPHERE®+ cryoablation probe, leveraging new insulation technology to reduce freeze times by 25% versus AtriCure's legacy cryoSHPERE® device. The product is currently in an extended limited launch period in the United States, wit.
AtriCure Announces Launch of the cryoSPHERE®+ Probe for Post-Operative Pain Management
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has launched the cryoSPHERE®+ cryoablation probe, leveraging new insulation technology to reduce freeze times by 25% versus AtriCure's legacy cryoSHPERE® device. The product is currently in an extended limited launch period in the United States, wit.
04/10 08:00 EST - businesswire.com
AtriCure to Announce First Quarter 2024 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter 2024 financial results on Wednesday, May 1, 2024. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Wednesday, May 1, 2024, to discuss its first quarter 2024 financial results. Those interested in listen.
AtriCure to Announce First Quarter 2024 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter 2024 financial results on Wednesday, May 1, 2024. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Wednesday, May 1, 2024, to discuss its first quarter 2024 financial results. Those interested in listen.
02/15 22:30 EST - seekingalpha.com
AtriCure, Inc. (ATRC) Q4 2023 Earnings Call Transcript
AtriCure, Inc. (ATRC) Q4 2023 Earnings Call Transcript
AtriCure, Inc. (ATRC) Q4 2023 Earnings Call Transcript
AtriCure, Inc. (ATRC) Q4 2023 Earnings Call Transcript
02/15 20:01 EST - zacks.com
Here's What Key Metrics Tell Us About AtriCure (ATRC) Q4 Earnings
The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Here's What Key Metrics Tell Us About AtriCure (ATRC) Q4 Earnings
The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.